Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours

NCT05459844 is registered in ClinicalTrials.gov with Sinotau Pharmaceutical Group as lead sponsor.

NCT NCT05459844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05459844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours
Lead sponsor
Sinotau Pharmaceutical Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 31, 2022
Completion date
December 31, 2028
Enrollment
196 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors